Literature DB >> 9619526

Effects of long-term low-dose mifepristone on reproductive function in women.

H B Croxatto1, L Kovács, R Massai, B A Resch, B Fuentealba, A M Salvatierra, H D Croxatto, S Zalányi, S Viski, L Krenács.   

Abstract

Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.

Entities:  

Keywords:  Americas; Biology; Chile; Clinical Research; Contraception; Contraception Research; Contraceptive Mode Of Action; Developing Countries; Endocrine System; Endometrial Effects; Endometrium; Family Planning; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Latin America; Menstrual Cycle; Menstruation; Ovarian Effects; Ovary; Ovulation Suppression; Physiology; Reproduction; Research Methodology; Research Report; Ru-486--administraction and dosage; South America; Urogenital System; Uterus

Mesh:

Substances:

Year:  1998        PMID: 9619526     DOI: 10.1093/humrep/13.4.793

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone.

Authors:  Julietta Fiscella; Thomas Bonfiglio; Paul Winters; Steven H Eisinger; Kevin Fiscella
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

2.  Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.

Authors:  Vivian Brache; Regine Sitruk-Ware; Alistair Williams; Diana Blithe; Horacio Croxatto; Narender Kumar; Sushma Kumar; Yun-Yen Tsong; Irving Sivin; Anita Nath; Heather Sussman; Leila Cochon; Maria Jose Miranda; Verónica Reyes; Anibal Faundes; Daniel Mishell
Journal:  Contraception       Date:  2011-12-15       Impact factor: 3.375

3.  ANP promotes proliferation and inhibits apoptosis of ovarian granulosa cells by NPRA/PGRMC1/EGFR complex and improves ovary functions of PCOS rats.

Authors:  Qin Zheng; Yulin Li; Dandan Zhang; Xinyuan Cui; Kuixing Dai; Yu Yang; Shuai Liu; Jichun Tan; Qiu Yan
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.